Rankings
▼
Calendar
ESLA Q1 2024 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena
ESLA
Estrella Immunopharma, Inc.
$53M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$469,530
Net Income
-$469,530
EPS (Diluted)
$-0.01
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$9M
Total Liabilities
$138,491
Stockholders' Equity
$8M
Cash & Equivalents
$5M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$469,530
-$149,650
-213.8%
Net Income
-$469,530
-$63,325
-641.5%
← FY 2024
All Quarters
Q2 2024 →